Joshua Patterson
Keine laufenden Positionen mehr
Vermögen: 10 155 $ am 31.03.2024
Profil
Mr. Joshua F.
Patterson was previously employed as a Chief Compliance Officer & General Counsel by Gamida Cell Ltd., a General Counsel by Akcea Therapeutics, Inc., an Executive Director & Deputy General Counsel by Ionis Pharmaceuticals, Inc., and an In-House Counsel by Amylin Pharmaceuticals, Inc. He received his undergraduate degree from Carthage College and a graduate degree from Syracuse University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
GAMIDA CELL LTD.
0,21% | 15.03.2024 | 282 096 ( 0,21% ) | 10 155 $ | 31.03.2024 |
Ehemalige bekannte Positionen von Joshua Patterson
| Unternehmen | Position | Ende |
|---|---|---|
| GAMIDA CELL LTD. | Compliance Officer | 26.04.2024 |
| IONIS PHARMACEUTICALS, INC. | Director/Board Member | 01.03.2018 |
Amylin Pharmaceuticals, Inc.
 Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01.09.2006 |
| AKCEA THERAPEUTICS, INC. | General Counsel | - |
Ausbildung von Joshua Patterson
| Carthage College | Undergraduate Degree |
| Syracuse University | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| IONIS PHARMACEUTICALS, INC. | Health Technology |
| GAMIDA CELL LTD. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Health Technology |
Akcea Therapeutics, Inc.
 Akcea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Akcea Therapeutics, Inc. is a biopharmaceutical company. It engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA. | Health Technology |
